Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression.
For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside-exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54%-100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.
Bangsberg
David R
DR
Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, and the Positive Health Program, San Francisco General Hospital, University of California, San Francisco, CA 94143-1372, USA. db@epi-center.ucsf.edu
D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000494:pharmacology*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors